左主干暨冠状动脉分叉病变峰会，CBS2019 - CBS 2019

HOME
CBS 2019
At CBS

General Information

Left Main & Coronary Bifurcation Summit (CBS) was founded in 2006 as a think tank dedicated to the treatment of left main and coronary bifurcation lesions. CBS aims to improve cardiological care by refreshing fundamental researches, clinical trials, yearly published guidelines, emerged ideas and case-based discussion.

Association and Affiliations
- Organized by
  
  Nanjing Heart Center
  
  Asian Bifurcation Club (ABC)
  
  Nanjing First Hospital, Nanjing Medical University
- Co-organized by
  
  Chinese Society of Cardiology (CSC)
  
  Capacity Building and Continuing Education Center,National Health and Family Planning Commission (CBCEC)
  
  American Society for Cardiovascular Angiography and Interventions (SCAI)
  
  Asian Heart Society (AHS)
Contact Us
- Registration Administration of Domestic Representatives
  
  Hongjuan Peng : +86-13913895477
  
  Haimei Xu +86-13914736846
  
  cbsnj@cbsmd.cn
- Registration Administration of Overseas Representatives
  
  Ling Lin : +86 (25) 52271398
  
  +86-13951884596
  
  cbs@cbsmd.cn
- Management of Challenging Cases
  
  Yingying Zhao :+86-13815408517
  
  sub@cbsmd.cn
Address

CBS2019 Congress Secretariat, Nanjing First Hospital, Building No.9 68# Changle Road, Nanjing, China

210006
FACULTY
FACULTY

General Chairman
Congress Chairman
Course Directors International Faculty Domestic Faculty Hong Kong and Taiwan Faculty Members of Academic Committee
Education Center

Education Center

• Online Education (For more customized user interface with self-defined collection of research papers and education resources.)

• CBS Education Resource

• CBSMD Scientific Library
SCIENTIFIC LIBRARY

SCIENTIFIC LIBRARY

Research Paper

> Acute Coronary Syndrom

> ASCVD Prevention

> Bifurcation Stenting

> Cardio-Oncology

> Congestive Heart Failure

> DAPT Duration

> Drug Coated Balloon

> Fractional Flow Reserve

> IVUS Guidance

> Optical Coherence Tomography

> Pulmonary Hypertension

> Rotational Atherectomy

> Shear Stress

> Stenting Left Main

> Transcatheter Aortic Valve Replacement

> Percutaneous LAA Occlusion

> Mitral/Tricuspid Valvular Disease

> Other Relevant Articles

Recommended Paper

Management of Acute Myocardial Infarction During the COVID-19 Pandemic

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up

CSC Expert Consensus on Principles of Clinical Management of Patients with Severe Emergent Cardiovascular Diseases during the COVID-19 Epidemic

ACC Clinical Bulletin Focuses on Cardiac Implications of Coronavirus (COVID-19)

HOME | SCIENTIFIC LIBRARY | Congestive Heart Failure

Congestive Heart Failure

Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure Nocturnal thoracic volume overload and post-discharge outcomes in patients hospitalized for acute heart failure Cardiac Resynchronization Therapy and Ventricular Tachyarrhythmia Burden The pyruvate-lactate axis modulates cardiac hypertrophy and heart failure Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial When and how to use SGLT2 inhibitors in patients with HFrEF or chronic kidney disease Guideline‐Directed Medical Therapy for Patients With Heart Failure With Midrange Ejection Fraction: A Patient‐Pooled Analysis From the KorHF and KorAHF Registries

Sort by hits |<<... 9 10 11 12 13 14 15 ...>>|

Review Article2020 Sep 21;S0033-0620(20)30158-4.

JOURNAL：Prog Cardiovasc Dis. Article Link

Mechanical circulatory support devices in advanced heart failure: 2020 and beyond

JL Vieira, HO Ventura, MR Mehra et al. Keywords: advanced heart failure; cardiogenic shock; hemocompatibility; INTERMACS; LVAD; left ventricular assist device; mechanical circulatory support

ABSTRACT

Substantial progress in the field of mechanical circulatory support (MCS) has expanded the treatment options for patients with advanced-stage heart failure (HF). Currently available MCS devices can be implanted percutaneously or surgically. They can also be configured to support the left, right, or both ventricles, offering varying levels of circulatory support. Short-term temporary MCS devices are primarily used in high-risk percutaneous coronary intervention, cardiogenic shock, and post-cardiac arrest, while durable left ventricular assist systems (LVAS) are increasingly utilized either as a bridge-to-transplant, bridge to decision, or as a destination therapy. The evolution from older pulsatile devices to continuous-flow LVAS and the incorporation of smaller pumps, with no valves, fewer moving parts, and improved hemocompatibility has translated into improved clinical outcomes, greater durability, fewer adverse events, and reduced overall cost of care. However, despite marked advances in device design and clinical management, determining MCS candidacy is often difficult and requires the integration of clinical, biomarker, imaging, exercise, and hemodynamic data. This review aims to provide a summary of the current use of short-term and durable MCS devices in the treatment of advanced-stage HF, highlighting several aspects of LVAS support and the challenges that remain.

Abstract

Recommended Article

Mechanical circulatory support devices in advanced heart failure: 2020 and beyond

ABSTRACT